A study published by the New England Journal of Medicine found that a class of drugs already used in other conditions produced clinical responses in four patients with a severe immune disorder linked to thymoma.
The New England Journal of Medicine has posted findings from an observational study into a rare but serious complication of thymoma — a tumour that grows in the thymus gland, a small organ that sits behind the breastbone and plays a central role in the body’s immune system. Researchers found that the immune disruption associated with thymoma appears to be driven by activation of a specific signalling pathway involving a protein called interferon-γ (a chemical messenger that regulates immune responses).
Four patients whose condition was classified as severe were treated with Janus kinase 1/2 inhibitors — a group of medicines that block the chemical signals behind certain types of immune overactivity. According to the journal, those patients showed both clinical improvement and changes in biomarkers, the measurable biological indicators doctors use to track disease activity.
The study is observational, meaning researchers recorded what happened to patients rather than running a controlled trial with a comparison group. That limits how far the findings can be generalised, and the patient numbers are small. The journal has not claimed the treatment is proven or ready for routine use.
Janus kinase inhibitors are already licensed in the UK for conditions including rheumatoid arthritis and certain blood disorders, though their use in thymoma-related immune dysregulation (disruption of normal immune function) would be outside those existing approvals at this stage.
Source: @NEJM